| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5741803 | SB PHARMCO | Substituted thiazolidinedionle derivatives |
Apr, 2015
(9 years ago) | |
|
US5741803 (Pediatric) | SB PHARMCO | Substituted thiazolidinedionle derivatives |
Oct, 2015
(8 years ago) | |
| US7358366 | SB PHARMCO | Thiazolidinedione derivative and its use as antidiabetic |
Apr, 2020
(4 years ago) | |
|
US7358366 (Pediatric) | SB PHARMCO | Thiazolidinedione derivative and its use as antidiabetic |
Oct, 2020
(3 years ago) | |
Avandaryl is owned by Sb Pharmco.
Avandaryl contains Glimepiride; Rosiglitazone Maleate.
Avandaryl has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Avandaryl are:
- US5741803
- US5741803*PED
- US7358366
- US7358366*PED
Avandaryl was authorised for market use on 23 November, 2005.
Avandaryl is available in tablet;oral dosage forms.
Avandaryl can be used as to improve glycemic control in patients with type 2 diabetes mellitus.
The generics of Avandaryl are possible to be released after 19 October, 2020.
Drugs and Companies using GLIMEPIRIDE; ROSIGLITAZONE MALEATE ingredient
Market Authorisation Date: 23 November, 2005
Treatment: To improve glycemic control in patients with type 2 diabetes mellitus
Dosage: TABLET;ORAL
AVANDARYL family patents
